BIO-TECH Systems, Inc. - Report #240: The Market for PET Radiopharmaceuticals & PET Imaging

Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes

Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189


	HOME

	ABOUT BIO-TECH SYSTEMS

	AUTHOR'S C.V.

	BREAKING MARKET NEWS

	REPORT #270 The U.S. Market for Diagnostic Radiopharmaceuticals New! Released in Nov. 2007!

	REPORT #260 The U.S. Market for Medical Imaging Contrast Media New! Released in Mar. 2007!

	REPORT #240 The Market for PET Radiopharmaceuticals & PET Imaging
Report Contents
Partial List of Exhibits

	REPORT #230 The World Market for Therapeutic Radiopharmaceuticals

	REPORT #170 The U.S. Market for Brachytherapy Products

	ORDERS

	NEWS RELEASES

	CONTACT US

THE MARKET FOR PET RADIOPHARMACEUTICALS & PET IMAGING

BIO-TECH SYSTEMS INC. announces the publication of:

BIO-TECH Report #240,
The Market for PET Radiopharmaceuticals & PET Imaging

The PET Report Includes:

Present and Emerging Markets for PET Imaging
Analysis of Current and Future FDG Sales
New Prospects for PET Procedures
New Targeted Tracers and Molecular Probes for PET
US and Worldwide Markets for PET Scanners
Growth of Rubidium PET Market for Cardiology
Market Trends Toward High Performace PET-CT Systems
Continued Growth in International Sales
Technological Trends and Competitive Challenges
Market Assessment and Sales Forecasts to 2012

The report has a strong focus on new products and technology and emerging market opportunities. The overlap between PET and radiology, which was stimulated by the success of combined PET-CT systems, has allowed radiologists to promote the advantages of multi-modality imaging to both patients and investors in PET imaging facilities. As the availability of PET increases and its capabilities become more visible to referring physicians, it will encourage procedure growth in oncology as well as cardiology and neurology. Recent approval of the National Oncologic PET Registry (NOPR) will help expand indications for PET and increase eligibility for reimbursement for many PET providers. New PET radiopharmaceuticals and molecular tracers are also in the pipeline that will measure biochemical processes that show patient response to therapy. This will overcome some of the limitations of conventional FDG-PET and allow measurement of cellular response to therapy rather than metabolism. This will aid in treatment monitoring and therapy planning for breast cancer, prostate cancer, brain cancer, bone cancer, and other common cancers.

Growth of PET Procedure Volume and Sales of FDG
The demand for PET continued to grow in 2005 reaching 1.2 million procedures, an increase of 24% for the year. Growth should continue with procedure volume increasing 31% in 2006. By 2012, PET procedure volume should rise to 4.4 million procedures. Approval of new indications in oncology have added to procedure volume as well as expanded use of PET in lung cancer, breast cancer, colon cancer, lymphoma and melanoma. Although the dominant focus of PET is still in oncology, applications in cardiology are increasing, particularly rubidium PET studies for myocardial perfusion. Myocardial viability studies with PET will also benefit from the introduction of fast, multi-slice PET-CT’s suitable for cardiac imaging. PET has also become more accessible to a wider base of physicians and patients, increasing the referral base. This has stimulated sales of FDG, while reducing the cost per dose. FDG sales of $259 million in 2005 will increase 31% in 2006 to $340 million and reach $933 million by 2012. These estimates are conservative and are based on present utilization. It is likely that new indications in oncology and cardiology as well as neurology will add further stimulus to the market for PET and FDG.

Sales Growth of PET Imaging Systems
In 2005, there were 326 PET scanners sold domestically and 608 scanners sold worldwide. US sales were $534.9 million and worldwide sales were $985.5 million. Domestic sales increased 13.0% from the previous year and worldwide sales increased 15.8%. The continued growth in PET orders is encouraging notwithstanding the excess equipment capacity as users attempt to increase the referral base. International sales have increased rapidly, with growth rates higher than the US. This reflects growing awareness of PET and expanded reimbursement, particularly in Japan. Both US and international users have adopted PET-CT very rapidly. In 2005, PET-CT comprised about 95% of total billings. By 2012, domestic bookings will increase to 550 units with sales of $907.5 million. Worldwide bookings will reach 1,095 units and $1,807 million in sales volume. The proportion of international sales will continue to rise from 45% in 2005 to 50% or higher by 2012. In 2005, 25% of all PET scanner sales were mobiles, comprising $133 million in sales. This level of activity should continue, with mobile sales providing an important underpinning in the PET market.

Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #240. If you are interested in purchasing BIO-TECH Report #240, please follow this link to our Online Order Form.

To download a detailed Table of Contents (TOC) for BIO-TECH Report #240, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.

Download TOC in MS Word format (40KB)

Download TOC in Adobe PDF format (25KB)

Report Contents | Partial List of Exhibits

Report #240 Home Page

Download Report #240 Table of Contents:

BTSI240.doc -OR-

BTSI240.pdf

Send this page to a friend